About US
Contact us
-
Private equity owners put for-sale sign on U.K.'s RosemontShopping for a drug company that's adept at making liquid formulas? You're in luck, because privately held Rosemont Pharmaceuticals is on the block. Owned by Close Brothers Private Equity, the drugmak2012/9/25
-
Report says Canadian drug market getting hCanadamay not have a huge drug market for pharma to target, but it has a growing one. That is the forecast from consulting firm GlobalData, which projects drug sales more than doubling to $45.9 billio2012/9/24
-
UPDATED: EU gives recommendation for Regeneron's EyleaRegeneron Pharmaceuticals ($REGN)has been giving Roche($RHHBY)fits with itsEyleadrug, stealing market share from the Swiss drugmaker'sLucentis. It appears that Regeneron will battle Lucentis in a new2012/9/24
-
Report: Roche's Zelboraf, BMS' Yervoy control their segmentA new market report saysYervoyfrom Bristol-Myers Squibb ($BMY) andZelboraffrom Roche ($RHHBY) have sewn up two-thirds of the market for treating advanced malignantmelanomaand will underpin significant2012/9/24
-
Bayer takes aim at J&J's Evra with new birth control patchBayer, already one of the biggest players in the $8 billion a yearcontraceptivedrug market, is aiming to take on Johnson & Johnson ($JNJ) in Europe with a transparentbirth controlpatch. The Germa2012/9/21
-
Roche hands NYC a biotech coup with new R&D siteSo long, Nutley. Hello, Big Apple. Roche ($RHHBY) is moving its whittled-down East Coast R&D group from New Jersey to a new life sciences complex in Manhattan, which beat out some fierce competiti2012/9/21
-
SFDA Deputy Commissioner Wu Zhen and Deputy Commissioner Sun Xianze meet with the delegation of Thai FDAOn the morning of September 12, 2012, SFDA Deputy Commissioner Wu Zhen and Deputy Commissioner Sun Xianze respectively met with the delegation led by Dr. Narangsant Pheerakij, Deputy Secretary-General2012/9/20
-
Lawyers seek to force J&J chief onto the stand in Risperdal caseShould Johnson & Johnson ($JNJ) CEOAlex Gorskyhave to take the stand in aRisperdalliability case? Lawyers for a Texas teen suing the company are demanding Gorsky's presence in court, saying he is2012/9/20
-
Does $1B really make a blockbuster anymore?When is a blockbuster not a blockbuster? When its sales are adjusted for inflation--or for share of the global pharma market. That $1 billion blockbuster threshold might have been a lofty goal in 192012/9/19
-
J&J to scout early-stage deals in 4 biotech hotspotsJohnson & Johnson never has made much of a mark in the sphere of early drug development. But now J&J ($JNJ) is thinking globally and acting locally, creating a plan to become a more prominent2012/9/19